Compare RBBN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | RGNX |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 418.1M |
| IPO Year | 2017 | 2015 |
| Metric | RBBN | RGNX |
|---|---|---|
| Price | $2.62 | $8.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.67 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.0M | 495.0K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | 18.08 |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $1.97 | $51.21 |
| Revenue Next Year | $6.69 | $19.08 |
| P/E Ratio | $10.84 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $1.83 | $6.89 |
| 52 Week High | $4.29 | $16.19 |
| Indicator | RBBN | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 51.02 |
| Support Level | $2.05 | $7.68 |
| Resistance Level | $2.93 | $9.41 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 41.67 | 53.95 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.